Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenith DrugsNSE:ZENITHDRUG 35 PS Ratio is 0.49 as of Jul. 24, 2026, which is 44% below its 10-year median of 0.87. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 35/100. The stock has 8 warning signs investors should review. Among 952 Drug Manufacturers companies, Zenith Drugs ranks better than 87.82% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Zenith Drugs's share price is ₹48.95.
Zenith Drugs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹99.94. Hence, Zenith Drugs's PS Ratio for today is 0.49.
The historical rank and industry rank for Zenith Drugs's PS Ratio or its related term are showing as below:
NSE:ZENITHDRUG'
s PS Ratio Range Over the Past 10 Years
Min: 0.39 Med: 0.87 Max: 1.84
Current: 0.5
During the past 6 years, Zenith Drugs's highest PS Ratio was 1.84. The lowest was 0.39. And the median was 0.87.
NSE:ZENITHDRUG's PS Ratio is ranked better than 87.82% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.295
vs NSE:ZENITHDRUG: 0.50
During the past 12 months, the average Revenue per Share Growth Rate of Zenith Drugs was 28.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 14.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 17.00% per year.
During the past 6 years, Zenith Drugs's highest 3-Year average Revenue per Share Growth Rate was 21.50% per year. The lowest was 13.30% per year. And the median was 14.40% per year.
Back to Basics: PS Ratio
Zenith Drugs (NSE:ZENITHDRUG) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Zenith Drugs PS Ratio Related Terms
Zenith Drugs PS Ratio Historical Data
* Premium members only.
The historical data trend for Zenith Drugs's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zenith Drugs's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Drugs PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zenith Drugs's PS Ratio distribution charts can be found below:
* The bar in red indicates where Zenith Drugs's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Zenith Drugs's PS Ratio for today is calculated as
Zenith Drugs's Share Price of today is ₹48.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zenith Drugs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹99.94.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Zenith Drugs (NSE:ZENITHDRUG) has a PS Ratio of 0.49 as of Jul. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zenith Drugs and its competitors. This is 44% below median its historical median of 0.87. Over the past decade, Zenith Drugs' PS Ratio has ranged from 0.39 to 1.84. According to the industry distribution chart, Zenith Drugs ranks #116 out of 952 companies in the Drug Manufacturers industry, placing it in the top 12.2%.
Is Zenith Drugs' PS Ratio too high?
Zenith Drugs' current PS Ratio of 0.49 is 44% below median its 10-year median of 0.87. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 1.84. The Drug Manufacturers industry median PS Ratio is 2.30. Zenith Drugs' value of 0.49 is 78.6% below this industry median. Based on the distribution chart, Zenith Drugs ranks #116 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zenith Drugs has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zenith Drugs ranks #116 out of 952 companies for PS Ratio. This places Zenith Drugs in the top 12% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.30. Zenith Drugs' value of 0.49 is 78.6% below this benchmark. Historically, Zenith Drugs' own PS Ratio has ranged from 0.39 to 1.84 over the past decade. While the company's 10-year median is 0.87 vs. the industry median of 2.30, Zenith Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenith Drugs's current PS Ratio of 0.49 is 78.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zenith Drugs and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenith Drugs's current PS Ratio is 0.49, which is 44% below median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current PS Ratio of 0.49. The current PS Ratio is 0.49, which is 44% below median its 10-year median of 0.87 and 78.6% below the Drug Manufacturers industry median of 2.30. Zenith Drugs' overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current PS Ratio is 0.49 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
35GF Score
Get the complete analysis for NSE:ZENITHDRUG
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZENITHDRUG has been successfully added to your 
